Targeting KRAS-Mutant Lung Cancers
Journal of the National Comprehensive Cancer Network · 2026
DOI: 10.6004/jnccn.2026.7038 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026. Verfasst von Edoardo Garbo und 6 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Lung Neoplasms, Proto-Oncogene Proteins p21(ras), Mutation, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 66 Literaturangaben.
Abstract (Originalsprache)
KRAS mutations are the most common oncogenic driver alterations in non–small cell lung cancer (NSCLC) and define biologically heterogeneous diseases shaped by mutation subtype, co-mutation patterns, and immune contexture. Recent advances in structural and chemical biology have transformed KRAS from an undruggable target into a rapidly expanding therapeutic vulnerability. The first allele-specific inhibitors, sotorasib and adagrasib, validated KRAS G12C as a druggable dependency, changing the treatment paradigm for previously treated KRAS G12C NSCLC, although primary, acquired, and adaptive resistance remain widespread. Next-generation inhibitors such as divarasib improve potency and tolerability but continue to face resistance through secondary KRAS alterations, bypass receptor tyrosine kinase (RTK) signaling, and adaptive MAPK reactivation. These challenges have spurred the development of KRAS(ON) inhibitors, dual ON/OFF inhibitors, and broader pan- KRAS and pan- RAS agents capable of targeting multiple oncogenic variants, including G12D, G12V, G12X, G13X, and Q61X. Early clinical results with tricomplex RAS(ON) inhibitors (eg, daraxonrasib) and G12D-selective agents (eg, zoldonrasib) demonstrate promising activity in subsets historically lacking targeted options. In parallel, rational combination strategies aimed at enhancing overall efficacy, such as RTK, SHP2/SOS1, or PD-1/PD-L1 blockade, together with emerging modalities including RAF–MEK clamps, adoptive cell therapies, and KRAS vaccines, are broadening the therapeutic landscape. This review comprehensively summarizes KRAS biology, therapeutic advances, mechanisms of resistance, and emerging strategies that are reshaping the treatment landscape of KRAS -mutant NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
- 2Department of Oncology, University of Torino, S. Luigi Gonzaga Hospital, Orbassano, Italy.
- 3Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
- 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Zitieren
APA
Garbo, E., Scaparone, P., Hoe, H. J., Luo, J., Shaw, A. T., Ambrogio, C., & Ricciuti, B. (2026). Targeting KRAS-Mutant Lung Cancers. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2026.7038
Vancouver
Garbo E, Scaparone P, Hoe HJ, Luo J, Shaw AT, Ambrogio C, et al. Targeting KRAS-Mutant Lung Cancers. Journal of the National Comprehensive Cancer Network. 2026. doi:10.6004/jnccn.2026.7038
BibTeX
@article{Garbo2026,
author = {Garbo, Edoardo and Scaparone, Pietro and Hoe, Hui Jing and Luo, Jia and Shaw, Alice T and Ambrogio, Chiara and Ricciuti, Biagio},
title = {Targeting KRAS-Mutant Lung Cancers},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
doi = {10.6004/jnccn.2026.7038}
}
EUVIMED